SAN FRANCISCO & PHILADELPHIA–(BUSINESS WIRE)–Biopharmaceutical corporations routinely treatment ailments in animals throughout preclinical testing, but those self same therapies fail in human scientific trials almost 95% of the time. By shifting from animals to an completely human optimization preclinical course of, Vivodyne has raised $40 million in new Collection A financing to scale its robotics+AI method to testing on hundreds of lab-grown, fully-functional human tissues, and the huge quantity of human knowledge
发布者：Dr.Durant，转转请注明出处：https://robotalks.cn/vivodyne-to-replace-animal-testing-with-40-million-funding-to-reverse-95-clinical-trial-failure-rate/
